Who Exports Hydroxychloroquine from India — 163 Suppliers Behind a $141.5M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for the production of Active Pharmaceutical Ingredients (APIs). The city's pharmaceutical ecosystem is characterized by a concentration of API manufacturers, including companies like Granules India, which specializes in APIs and pharmaceutical formulation intermediates. This robust infrastructure positions Hyderabad as a key player in the supply chain for drugs like hydroxychloroquine, ensuring a steady production of essential APIs.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Major companies such as Zydus Lifesciences Limited (formerly Cadila Healthcare Limited) and Alembic Pharmaceuticals are headquartered here. Zydus Lifesciences, for instance, has been a significant contributor to hydroxychloroquine exports, accounting for 82.5% of total exports valued at $116.8 million between 2022 and 2026. The region's emphasis on formulations complements the API production in Hyderabad, facilitating a seamless transition from raw materials to finished products.

The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products. Its proximity to major ports and well-established logistics infrastructure make it an ideal location for companies aiming to distribute their products globally. This region's strategic importance is underscored by its role in facilitating the export of hydroxychloroquine to various countries, including the United States, which accounted for 89.2% of India's hydroxychloroquine exports during the specified period.

Located in Himachal Pradesh, the Baddi-Nalagarh region has emerged as a significant pharmaceutical manufacturing zone, largely due to favorable tax incentives offered by the government. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units, contributing to the overall production capacity of drugs, including hydroxychloroquine. The region's growth underscores the impact of policy measures in bolstering pharmaceutical manufacturing capabilities.

• Diversify Supplier Base: While Zydus Lifesciences Limited is the dominant exporter of hydroxychloroquine, accounting for 82.5% of exports, it's prudent to engage with other suppliers such as IPCA Laboratories Limited and Cadila Healthcare Limited to mitigate supply chain risks.

• Monitor Regulatory Changes: Stay informed about export policies and regulatory changes. For instance, India lifted the export ban on hydroxychloroquine on June 18, 2020, which had significant implications for global supply chains.

• Leverage Regional Strengths: Utilize the API production capabilities of Hyderabad and the formulation expertise of the Ahmedabad-Vadodara corridor to ensure a robust and efficient supply chain for hydroxychloroquine.

• Assess Logistics Infrastructure: Given the export concentration to the United States, ensure that logistics and distribution channels, particularly through the Mumbai-Thane-Raigad region, are optimized for timely and efficient delivery.

By strategically engaging with these pharmaceutical clusters and adhering to the sourcing recommendations, stakeholders can enhance the resilience and efficiency of the hydroxychloroquine supply chain.